Enhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes
The regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have made these cells the focus of multiple pre-clinical studies and clinical trials. While the results from these clinical studies have established that MSCs are safe, the efficacy of these cells is not as well-establ...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_92076 | ||
| 005 | 20220916 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220916s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4995-8 | ||
| 020 | |a 9783036549965 | ||
| 020 | |a 9783036549958 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4995-8 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Ylostalo, Joni H. |4 edt | |
| 700 | 1 | |a Durand, Nisha C. |4 edt | |
| 700 | 1 | |a Ylostalo, Joni H. |4 oth | |
| 700 | 1 | |a Durand, Nisha C. |4 oth | |
| 245 | 1 | 0 | |a Enhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes |
| 260 | |a Basel |c 2022 | ||
| 300 | |a 1 electronic resource (204 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have made these cells the focus of multiple pre-clinical studies and clinical trials. While the results from these clinical studies have established that MSCs are safe, the efficacy of these cells is not as well-established. In this regard, there have been increased efforts towards generating potentiated/activated MSCs with enhanced therapeutic efficacy. Research on the mechanisms for enhancing MSC potency and efficacy is an area of active study with great potential for translation into clinical settings. The purpose of this book is to bring together recent research from a broad range of topics relating to potentiation strategies for enhancing MSC therapeutic efficacy, including growth factor pre-conditioning, hypoxia, and 3D culture. The research compiled in this book increases the basic understanding of MSC culture techniques and describes some MSC preparations for potential novel therapeutic applications. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a cell therapy | ||
| 653 | |a immunomodulation | ||
| 653 | |a polyunsaturated fatty acid | ||
| 653 | |a CD206 | ||
| 653 | |a phagocytosis | ||
| 653 | |a mesenchymal stem cells | ||
| 653 | |a Vadadustat | ||
| 653 | |a AKB-6548 | ||
| 653 | |a preconditioning | ||
| 653 | |a priming | ||
| 653 | |a secretome | ||
| 653 | |a chemotaxis | ||
| 653 | |a Wharton's jelly mesenchymal stem cells | ||
| 653 | |a umbilical cord | ||
| 653 | |a oxygen conditions | ||
| 653 | |a secretory profile | ||
| 653 | |a neuroprotection | ||
| 653 | |a mesenchymal stromal cells | ||
| 653 | |a 3D culture | ||
| 653 | |a neurospheres | ||
| 653 | |a spheroids | ||
| 653 | |a pluripotency | ||
| 653 | |a neural | ||
| 653 | |a quiescence | ||
| 653 | |a mesothelioma | ||
| 653 | |a malignant pleural mesothelioma (MPM) | ||
| 653 | |a liver cirrhosis | ||
| 653 | |a placenta-derived mesenchymal stem cells | ||
| 653 | |a WKYMVm | ||
| 653 | |a combination therapy | ||
| 653 | |a iPSC-derived MSCs | ||
| 653 | |a iMSC secretome | ||
| 653 | |a pre-conditioning | ||
| 653 | |a angiogenesis | ||
| 653 | |a IFN-γ | ||
| 653 | |a hypoxia | ||
| 653 | |a potentiation of iMSC efficacy | ||
| 653 | |a nanofiber-hydrogel composite | ||
| 653 | |a spinal cord injury | ||
| 653 | |a inflammation | ||
| 653 | |a macrophages | ||
| 653 | |a secondary injury | ||
| 653 | |a astrocytes | ||
| 653 | |a axon growth | ||
| 653 | |a adipose tissue-derived stem cells (ASCs) | ||
| 653 | |a autophagy | ||
| 653 | |a rapamycin | ||
| 653 | |a 3-methyladenine | ||
| 653 | |a immunosuppression | ||
| 653 | |a exosome | ||
| 653 | |a engineered cardiac patches | ||
| 653 | |a adipose-derived stem cell | ||
| 653 | |a paracrine potential | ||
| 653 | |a osteogenic differentiation | ||
| 653 | |a hepatocyte growth factor | ||
| 653 | |a fibroblast growth factor 2 | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5952 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/92076 |7 0 |z DOAB: description of the publication |